Stock Track | Arrowhead Pharmaceuticals Plummets 5.08% Intraday on Widening Q1 Losses and Missed Expectations

Stock Track

Feb 12, 2025

Arrowhead Pharmaceuticals, a biopharmaceutical company focused on developing targeted RNA interference (RNAi) therapeutics, saw its stock plummet 5.08% in Wednesday's intraday trading session. This significant decline followed the company's disappointing first-quarter 2025 earnings report, which missed analysts' expectations and showcased widening losses.

The key financial highlights from the report were:

Net loss of $173.1 million, a 30% increase from the same quarter last year
Earnings per share loss of $1.39, further deteriorating from the $1.24 loss in Q1 2024
Revenue missed analyst estimates by a staggering 87%

Despite the challenging quarter, Arrowhead Pharmaceuticals remains optimistic about its future growth prospects. The company forecasts a 42% annual revenue growth rate on average for the next three years, outpacing the projected 21% growth for the broader US biotechnology industry.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1120725347"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120725347\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120725347?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120725347","market":"us","top_or_hot":-1,"title":"Stock Track | Arrowhead Pharmaceuticals Plummets 5.08% Intraday on Widening Q1 Losses and Missed Expectations","media":"Stock Track","content":"<p>Arrowhead Pharmaceuticals, a biopharmaceutical company focused on developing targeted RNA interference (RNAi) therapeutics, saw its stock plummet 5.08% in Wednesday's intraday trading session. This significant decline followed the company's disappointing first-quarter 2025 earnings report, which missed analysts' expectations and showcased widening losses.</p>\n\n<p>The key financial highlights from the report were:\n<ul>\n<li>Net loss of $173.1 million, a 30% increase from the same quarter last year</li>\n<li>Earnings per share loss of $1.39, further deteriorating from the $1.24 loss in Q1 2024</li>\n<li>Revenue missed analyst estimates by a staggering 87%</li>\n</ul>\n</p>\n\n<p>Despite the challenging quarter, Arrowhead Pharmaceuticals remains optimistic about its future growth prospects. The company forecasts a 42% annual revenue growth rate on average for the next three years, outpacing the projected 21% growth for the broader US biotechnology industry.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arrowhead Pharmaceuticals Plummets 5.08% Intraday on Widening Q1 Losses and Missed Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arrowhead Pharmaceuticals Plummets 5.08% Intraday on Widening Q1 Losses and Missed Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-12 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arrowhead Pharmaceuticals, a biopharmaceutical company focused on developing targeted RNA interference (RNAi) therapeutics, saw its stock plummet 5.08% in Wednesday's intraday trading session. This significant decline followed the company's disappointing first-quarter 2025 earnings report, which missed analysts' expectations and showcased widening losses.</p>\n\n<p>The key financial highlights from the report were:\n<ul>\n<li>Net loss of $173.1 million, a 30% increase from the same quarter last year</li>\n<li>Earnings per share loss of $1.39, further deteriorating from the $1.24 loss in Q1 2024</li>\n<li>Revenue missed analyst estimates by a staggering 87%</li>\n</ul>\n</p>\n\n<p>Despite the challenging quarter, Arrowhead Pharmaceuticals remains optimistic about its future growth prospects. The company forecasts a 42% annual revenue growth rate on average for the next three years, outpacing the projected 21% growth for the broader US biotechnology industry.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1120725347","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120725347","pubTimestamp":1739372539,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arrowhead Pharmaceuticals, a biopharmaceutical company focused on developing targeted RNA interference  therapeutics, saw its stock plummet 5.08% in Wednesday's intraday trading session. This significant decline followed the company's disappointing first-quarter 2025 earnings report, which missed analysts' expectations and showcased widening losses.The key financial highlights from the report were:. Net loss of $173.1 million, a 30% increase from the same quarter last year. Earnings per share lo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"个股赛道Arrowhead Pharmaceuticals盘中暴跌5.08%因Q1亏损扩大不及预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals, a biopharmaceutical company focused on developing targeted RNA interference (RNAi) therapeutics, saw its stock plummet 5.08% in Wednesday's intraday trading session. This significant decline followed the company's disappointing first-quarter 2025 earnings report, which missed analysts' expectations and showcased widening losses.\nThe key financial highlights from the report were:\n\nNet loss of $173.1 million, a 30% increase from the same quarter last year\nEarnings per share loss of $1.39, further deteriorating from the $1.24 loss in Q1 2024\nRevenue missed analyst estimates by a staggering 87%\n\nDespite the challenging quarter, Arrowhead Pharmaceuticals remains optimistic about its future growth prospects. The company forecasts a 42% annual revenue growth rate on average for the next three years, outpacing the projected 21% growth for the broader US biotechnology industry.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}